GNQ Insilico Unveils Multi-Pathway Therapeutic Formulation for ALS Leveraging proprietary Drug Assessment Platform
GNQ Insilico, Inc. (“GNQ” or “the Company”), a cutting-edge TechBio platform company, announced results from its proprietary Drug Assessment Platform. GNQ’s platform represents a breakthrough in computational drug development and due diligence, providing investors and pharmaceutical partners with unprecedented insights into multi-pathway therapeutic optimization. To demonstrate the platform’s transformative capabilities, GNQ has developed a novel, […]
